Industry Strength Score
56/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
DECOY THERAPEUTICS INC (DCOY) Stock Price & Overview
NASDAQ:DCOY • US79400X6022
Current stock price
6.05 USD
+0.51 (+9.21%)
Last:
The current stock price of DCOY is 6.05 USD. Today DCOY is up by 9.21%. In the past month the price decreased by -4.27%.
DCOY Key Statistics
1-Month Range5.15 - 6.7
Current DCOY stock price positioned within its 1-month range.
- Market Cap
- 3.207M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -593.79
- Dividend Yield
- N/A
DCOY Stock Performance
Today
+9.21%
1 Week
+11.62%
1 Month
-4.27%
3 Months
-34.60%
Longer-term
6 Months N/A
1 Year N/A
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A
DCOY Stock Chart
DCOY Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to DCOY.
Chartmill TA Rating
Chartmill Setup Rating
DCOY Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to DCOY. While DCOY seems to be doing ok healthwise, there are quite some concerns on its profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
DCOY Earnings
Next Earnings DateMay 12, 2026
Last Earnings DateMar 31, 2026
PeriodQ4 / 2025
EPS Reported
Revenue Reported
EPS Surprise %
Revenue Surprise %
DCOY Forecast & Estimates
6 analysts have analysed DCOY and the average price target is 30.6 USD. This implies a price increase of 405.79% is expected in the next year compared to the current price of 6.05.
Analysts
Analysts43.33
Price Target30.6 (405.79%)
EPS Next Y-126.98%
Revenue Next YearN/A
DCOY Financial Highlights
Over the last trailing twelve months DCOY reported a non-GAAP Earnings per Share(EPS) of -593.79. The EPS increased by 55.51% compared to the year before.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)-12.52M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -113.22% | ||
| ROE | -212.57% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%-67.73%
Sales Q2Q%N/A
EPS 1Y (TTM)55.51%
Revenue 1Y (TTM)N/A
DCOY Ownership
Ownership
Inst Owners12.35%
Shares530.00K
Float530.00K
Ins Owners0.59%
Short Float %4.39%
Short Ratio0.41
DCOY Industry Overview
DCOY operates in the Biotechnology sub-industry within the Health Care sector. This group contains 416 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
13/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
27%
Outperformed 27% of sub-industries
3 Month Rank
47%
Outperformed 47% of sub-industries
6 Month Rank
30%
Outperformed 30% of sub-industries
Industry Fundamentals & Breadth
- Members
- 416
- New Highs
- 4.1%
- New Lows
- 4.6%
- Average ROE
- 48.3%
- Average Profit Margin
- 20.7%
- Average Operating Margin
- 33.6%
- Average P/E
- 26.4
- Average Fwd P/E
- 22.3
- Average Debt/Equity
- 2.2
DCOY Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 12.88 | 360.632B | ||
| AMGN | AMGEN INC | 15.16 | 182.426B | ||
| GILD | GILEAD SCIENCES INC | 14.8 | 159.919B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.94 | 107.655B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.82 | 72.562B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.34 | 40.188B | ||
| INSM | INSMED INC | N/A | 29.146B | ||
| BIIB | BIOGEN INC | 11.58 | 28.527B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 27.853B | ||
| NTRA | NATERA INC | N/A | 27.602B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.55 | 25.03B | ||
| INCY | INCYTE CORP | 10.43 | 19.722B | ||
| MRNA | MODERNA INC | N/A | 18.132B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About DCOY
Company Profile
Decoy Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Houston, Texas and currently employs 2 full-time employees. The company went IPO on 2015-01-29. Decoy Therapeutics Inc., formerly Salarius Pharmaceuticals, Inc., is a preclinical-stage biotechnology company that is leveraging machine learning and artificial intelligence (AI) tools alongside high-speed synthesis techniques to design, engineer and manufacture peptide conjugate drug candidates that target serious unmet medical needs. The Company’s initial pipeline is focused on respiratory viruses and GI cancers. In parallel, the Company is advancing discovery programs, including multi-virus decoy candidates designed to address overlapping respiratory threats, and cell-based and organoid-level validation of novel G protein-coupled receptor (GPCR)-targeted drug candidates outside of antivirals.
Company Info
IPO: 2015-01-29
DECOY THERAPEUTICS INC
2450 Holcombe Blvd Ste J-608
Houston TEXAS US
Employees: 2
Phone: 13026587581
DECOY THERAPEUTICS INC / DCOY FAQ
What does DCOY do?
Decoy Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Houston, Texas and currently employs 2 full-time employees. The company went IPO on 2015-01-29. Decoy Therapeutics Inc., formerly Salarius Pharmaceuticals, Inc., is a preclinical-stage biotechnology company that is leveraging machine learning and artificial intelligence (AI) tools alongside high-speed synthesis techniques to design, engineer and manufacture peptide conjugate drug candidates that target serious unmet medical needs. The Company’s initial pipeline is focused on respiratory viruses and GI cancers. In parallel, the Company is advancing discovery programs, including multi-virus decoy candidates designed to address overlapping respiratory threats, and cell-based and organoid-level validation of novel G protein-coupled receptor (GPCR)-targeted drug candidates outside of antivirals.
What is the stock price of DECOY THERAPEUTICS INC today?
The current stock price of DCOY is 6.05 USD. The price increased by 9.21% in the last trading session.
Does DCOY stock pay dividends?
DCOY does not pay a dividend.
What is the ChartMill technical and fundamental rating of DCOY stock?
DCOY has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is the Price/Earnings (PE) ratio of DECOY THERAPEUTICS INC (DCOY)?
DECOY THERAPEUTICS INC (DCOY) does not have a PE ratio as the earnings reported over the last twelve months were negative (-593.79).